Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT

Molecular Endocrinology

Volumn 25, Issue 1, 2011, Pages 138-156

  Herraiz, Cecilia ^a   Journé, Fabrice ^b   Abdel Malek, Zalfa ^c   Ghanem, Ghanem ^b   Jiménez Cervantes, Celia ^a   García Borrón, José C ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2',5' DIDEOXYADENOSINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 TERT BUTYLPHENYL N (4 IMIDAZOL 1 YL PHENYL)SULFONAMIDE; ADENYLATE CYCLASE INHIBITOR; ALPHA INTERMEDIN; BAYK 8644; CYCLIC AMP; FORSKOLIN; GTP 14564; ISCK 03; MELANOCORTIN 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NIFEDIPINE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE; RO 318425; SMALL INTERFERING RNA; STEM CELL FACTOR RECEPTOR; SULFONAMIDE; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME SYNTHESIS; GENE EXPRESSION PROFILING; HAIR COLOR; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; MOUSE; MUTANT; NONHUMAN; ONCOGENE C KIT; PHENOTYPE; PRIORITY JOURNAL; RED HAIR COLOR; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; TRANSACTIVATION; WILD TYPE;

ALPHA-MSH; ANIMALS; CELL LINE, TUMOR; CYCLIC AMP; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOCORTINS; MELANOCYTES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PC12 CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-KIT; RATS; RECEPTOR, MELANOCORTIN, TYPE 1; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANSCRIPTIONAL ACTIVATION;

EID: 78650881154     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2010-0217     Document Type: Article

References (88)

1. Slominski A, Tobin DJ, Shibahara S, Wortsman J 2004 Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84: 1155-1228
2. Yamaguchi Y, Brenner M, Hearing VJ 2007 The regulation of skin pigmentation. J Biol Chem 282: 27557-27561
3. Buscà R, Ballotti R 2000 Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res 13: 60-69
4. D'Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, Igras V, Kunisada T, Granter SR, Nishimura EK, Ito S, Fisher DE 2006 Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 443: 340-344
5. Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B, Macaron N, Arbiser JL 2002 Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8: 3728-3733
6. Böhm M, Moellmann G, Cheng E, Alvarez-Franco M, Wagner S, Sassone-Corsi P, Halaban R 1995 Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ 6: 291-302
7. Levy C, Khaled M, Fisher DE 2006 MITF: Master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12: 406-414
8. Rees JL 2004 The genetics of sun sensitivity in humans. Am J Hum Genet 75: 739-751
9. Ito S, Wakamatsu K 2003 Quantitative analysis of eumelanin and pheomelanin in humans, mice, and other animals: A comparative review. Pigment Cell Res 16: 523-531
10. Katz M, Amit I, Yarden Y 2007 Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta 1773: 1161-1176
11. Kyriakis JM, App H, Zhang XF, Banerjee P, Brautigan DL, Rapp UR, Avruch J 1992 Raf-1 activates MAP kinase-kinase. Nature 358: 417-421
12. Wellbrock C, Karasarides M, Marais R 2004 The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5: 875-885
13. Murphy LO, Blenis J 2006 MAPK signal specificity: The right place at the right time. Trends Biochem Sci 31: 268-275
14. Alsina J, Gorsk DH, Germino FJ, Shih W, Lu SE, Zhang ZG, Yang JM, Hait WN, Goydos JS 2003 Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin Cancer Res 9: 6419-6425
15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417: 949-954
16. Gray-Schopfer V, Wellbrock C, Marais R 2007 Melanoma biology and new targeted therapy. Nature 445: 851-857
17. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J 2002 Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: Mutations occur early and persist throughout tumor progression. Clin Cancer Res 8: 3468-3474
18. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A 2006 Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25: 3357-3364
19. Wehrle-Haller B 2003 The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res 16: 287-296
20. Bennett DC, Lamoreux ML 2003 The color loci of mice-a genetic century. Pigment Cell Res 16: 333-344
21. Spritz RA, Beighton P 1998 Piebaldism with deafness: Molecular evidence for an expanded syndrome. Am J Med Genet 75: 101-103
22. Syrris P, Heathcote K, Carrozzo R, Devriendt K, Elcioglu N, Garrett C, McEntagart M, Carter ND 2002 Human piebaldism: Six novel mutations of the proto-oncogene KIT. Hum Mutat 20: 234
23. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR 2007 L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121: 257-264
24. Huang S, Jean D, Luca M, Tainsky MA, Bar-Eli M 1998 Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J 17: 4358-4369 (Pubitemid 28362626)
25. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, UllrichA 1992 Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 52: 197-201
26. Lefkowitz RJ, Shenoy SK 2005 Transduction of receptor signals by β-arrestins. Science 308: 512-517
27. Marinissen MJ, Gutkind JS 2001 G-protein-coupled receptors and signaling networks: Emerging paradigms. Trends Pharmacol Sci 22: 368-376
28. Werry TD, Sexton PM, Christopoulos A 2005 "Ins and outs" of seven-transmembrane receptor signalling to ERK. Trends Endocrinol Metab 16: 26-33
29. Borrell-Pagès M, Rojo F, Albanell J, Baselga J, Arribas J 2003 TACE is required for the activation of the EGFR by TGF-β in tumors. EMBO J 22: 1114-1124
30. Wetzker R, Böhmer FD 2003 Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4: 651-657
31. Amsen EM, Pham N, Pak Y, Rotin D 2006 The guanine nucleotide exchange factor CNrasGEF regulates melanogenesis and cell survival in melanoma cells. J Biol Chem 281: 121-128
32. Buscà R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychène A, Ortonne JP, Ballotti R 2000 Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 19: 2900-2910
33. Englaro W, Rezzonico R, Durand-Clément M, Lallemand D, Ortonne JP, BallottiR1995 Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J Biol Chem 270: 24315-24320
34. Garcia-Borrón JC, Sánchez-Laorden BL, Jiménez- Cervantes C 2005 Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res 18: 393-410
35. Box NF, Wyeth JR, O'Gorman LE, Martin NG, Sturm RA 1997 Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet 6: 1891-1897
36. Duffy DL, Box NF, Chen W, Palmer JS, Montgomery GW, James MR, Hayward NK, Martin NG, Sturm RA 2004 Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet 13: 447-461
37. Healy E, Flannagan N, Ray A, Todd C, Jackson IJ, Matthews JN, Birch-Machin MA, Rees JL 2000 Melanocortin-1-receptor gene and sun sensitivity in individuals without red hair. Lancet 355: 1072-1073
38. Sturm RA 2002 Skin colour and skin cancer-MC1R, the genetic link. Melanoma Res 12: 405-416
39. Sturm RA, Duffy DL, Box NF, Chen W, Smit DJ, Brown DL, Stow JL, Leonard JH, Martin NG 2003 The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes. Pigment Cell Res 16: 266-272
40. Sturm RA, Duffy DL, Box NF, Newton RA, Shepherd AG, Chen W, Marks LH, Leonard JH, Martin NG 2003 Genetic association and cellular function of MC1R variant alleles in human pigmentation. Ann NY Acad Sci 994: 348-358
41. Beaumont KA, Shekar SN, Shekar SL, Newton RA, James MR, Stow JL, Duffy DL, Sturm RA 2007 Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Hum Mol Genet 16: 2249-2260
42. Healy E, Jordan SA, Budd PS, Suffolk R, Rees JL, Jackson IJ 2001 Functional variation of MC1R alleles from red-haired individuals. Hum Mol Genet 10: 2397-2402
43. Newton RA, Smit SE, Barnes CC, Pedley J, Parsons PG, Sturm RA 2005 Activation of the cAMP pathway by variant human MC1R alleles expressed in HEK and in melanoma cells. Peptides 26: 1818-1824
44. Sánchez-Laorden BL, Sánchez-Más J, Martínez-Alonso E, Martínez- Mená rguez JA, García-Borró n JC, Jiménez-Cervantes C 2006 Dimerization of the human melanocortin 1 receptor: Functional consequences and dominant-negative effects. J Invest Dermatol 126: 172-181
45. Sánchez-Laorden BL, Jiménez-Cervantes C, García-Borrón JC 2007 Regulation of human melanocortin 1 receptor signaling and trafficking by Thr-308 and Ser-316 and its alteration in variant alleles associated with red hair and skin cancer. J Biol Chem 282: 3241-3251
46. Sánchez-Laorden BL, Herraiz C, Valencia JC, Hearing VJ, Jiménez- Cervantes C, García-Borrón JC 2009 Aberrant trafficking of hu- man melanocortin 1 receptor variants associated with red hair and skin cancer: Steady-state retention of mutant forms in the proximal golgi. J Cell Physiol 220: 640-654
47. Sanchez Más J, Olivares Sánchez C, Ghanem G, Haycock J, Lozano Teruel JA, García-Borrón JC, Jiménez-Cervantes C 2002 Loss-offunction variants of the human melanocortin-1 receptor gene in melanoma cells define structural determinants of receptor function. Eur J Biochem 269: 6133-6141
48. Herraiz C, Jiménez-Cervantes C, Zanna P, García- Borrón JC 2009 Melanocortin 1 receptor mutations impact differentially on signalling to the cAMP and the ERK mitogen-activated protein kinase pathways. FEBS Lett 583: 3269-3274
49. Tada A, Pereira E, Beitner-Johnson D, Kavanagh R, Abdel-Malek ZA 2002 Mitogen- and ultraviolet-B-induced signaling pathways in normal human melanocytes. J Invest Dermatol 118: 316-322
50. Scott MC, Wakamatsu K, Ito S, Kadekaro AL, Kobayashi N, Groden J, Kavanagh R, Takakuwa T, Virador V, Hearing VJ, Abdel- Malek ZA 2002 Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation. J Cell Sci 115: 2349-2355
51. Eves P, Haycock J, Layton C, Wagner M, Kemp H, Szabo M, Morandini R, Ghanem G, García-Borrón JC, Jiménez-Cervantes C, MacNeil S 2003 Anti-inflammatory and anti-invasive effects of α-melanocyte- stimulating hormone in human melanoma cells. Br J Cancer 89: 2004-2015
52. Má s JS, Gerritsen I, Hahmann C, Jiménez-Cervantes C, García- Borrón JC 2003 Rate limiting factors in melanocortin 1 receptor signalling through the cAMP pathway. Pigment Cell Res 16: 540-547
53. Dumaz N, Marais R 2005 Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J 272: 3491-3504
54. Stork PJ, Schmitt JM 2002 Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12: 258-266
55. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, Bastian BC, Springer C, Marais R 2006 In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66: 9483-9491
56. Sun Y, McGarrigle D, Huang XY 2007 When a G protein-coupled receptor does not couple to a G protein. Mol Biosyst 3: 849-854
57. Ramsden JJ 2000 MARCKS: A case of molecular exaptation? Int J Biochem Cell Biol 32: 475-479
58. Kim CS, Lee SH, Kim RY, Kim BJ, Li SZ, Lee IH, Lee EJ, Lim SK, Bae YS, Lee W, Baik JH 2002 Identification of domains directing specificity of coupling to G-proteins for the melanocortin MC3 and MC4 receptors. J Biol Chem 277: 31310-31317
59. Wachira SJ, Hughes-Darden CA, Taylor CV, Ochillo R, Robinson TJ 2003 Evidence for the interaction of protein kinase C and melanocortin 3-receptor signaling pathways. Neuropeptides 37: 201-210
60. Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HD, Fry DW, Kraker AJ, Denny WA 1996 Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7- dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 39: 267-276
61. Roskoski Jr R 2005 Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 338: 1307-1315
62. Na YJ, Baek HS, Ahn SM, Shin HJ, Chang IS, Hwang JS 2007 [4-tbutylphenyl]- N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs. Biochem Pharmacol 74: 780-786
63. Lev S, Givol D, Yarden Y 1992 Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. Proc Natl Acad Sci USA 89: 678-682
64. Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T 2003 Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem 278: 32892-32898
65. Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu- Lowe D 2006 SU14813: A novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 5: 1774-1782
66. Kasamatsu S, Hachiya A, Higuchi K, Ohuchi A, Kitahara T, Boissy RE 2008 Production of the soluble form of KIT, s-KIT, abolishes stem cell factor-induced melanogenesis in human melanocytes. J Invest Dermatol 128: 1763-1772
67. Bromann PA, Korkaya H, Courtneidge SA 2004 The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23: 7957-7968
68. Ingley E 2008 Src family kinases: Regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 1784: 56-65
69. Roskoski Jr R 2004 Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 324: 1155-1164
70. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC 1999 Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3: 629-638
71. Karni R, Mizrachi S, Reiss-Sklan E, Gazit A, Livnah O, Levitzki A 2003 The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett 537: 47-52
72. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P 2007 The selectivity of protein kinase inhibitors: A further update. Biochem J 408: 297-315
73. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC 2006 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6- [4-(2-hydroxyethyl)- 1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3- thiazole-5- carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 49: 6819-6832
74. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C 2006 Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108: 286-291
75. Thommes K, Lennartsson J, Carlberg M, Ronnstrand L 1999 Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor. Biochem J 341(Pt 1): 211-216
76. Dhomen N, Marais R 2007 New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17: 31-39
77. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, Courtneidge SA 2000 SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 20: 9018-9027
78. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ 1999 c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274: 8335-8343
79. Hansen K, Johnell M, Siegbahn A, Rorsman C, Engström U, Wernstedt C, Heldin CH, Rönnstrand L 1996 Mutation of a Src phosphorylation site in the PDGF β-receptor leads to increased PDGFstimulated chemotaxis but decreased mitogenesis. EMBO J 15: 5299-5313
80. Lennartsson J, Wernstedt C, Engström U, Hellman U, Rönnstrand L 2003 Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent phosphorylation site mediating interaction with c- Crk. Exp Cell Res 288: 110-118
81. Daub H, Weiss FU, Wallasch C, Ullrich A 1996 Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379: 557-560
82. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE 1998 MAP kinase links the transcription factor microphthalmia to c-Kit signalling in melanocytes. Nature 391: 298-301
83. Englaro W, Bertolotto C, Buscà R, Brunet A, Pagès G, Ortonne JP, Ballotti R 1998 Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J Biol Chem 273: 9966-9970
84. Kadekaro AL, Kavanagh R, Kanto H, Terzieva S, Hauser J, Kobayashi N, Schwemberger S, Cornelius J, Babcock G, Shertzer HG, Scott G, Abdel-Malek ZA 2005 α-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res 65: 4292-4299
85. Hayward NK 2003 Genetics of melanoma predisposition. Oncogene 22: 3053-3062
86. Abdel-Malek Z, Swope V, Collins C, Boissy R, Zhao H, Nordlund J 1993 Contribution of melanogenic proteins to the heterogeneous pigmentation of human melanocytes. J Cell Sci 106(Pt 4): 1323-1331
87. Abdel-Malek Z, Swope VB, Suzuki I, Akcali C, Harriger MD, Boyce ST, Urabe K, Hearing VJ 1995 Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci USA 92: 1789-1793
88. Sánchez-Más J, Guillo LA, Zanna P, Jiménez-Cervantes C, García- Borrón JC 2005 Role of G protein-coupled receptor kinases in the homologous desensitization of the human and mouse melanocortin 1 receptors. Mol Endocrinol 19: 1035-1048